ASPI highlights expansion and targets over $300M 2031 EBITDA
ASPI says four divisions are scaling, citing proprietary enrichment tech at commercial scale and strong financial position. Milestones include new plant launches, global radiopharmacy expansion, and partnerships, plus a >$300M 2031 EBITDA target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.